AI in Respiratory Diseases Market Key Players Analysis - Siemens Healthineers, VIDA Diagnostics Inc,THIRONA, Infervision, icometrix. GE Healthcare.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI in Respiratory Diseases Market- (By Indication (Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Pulmonary Infection), By Imaging Type (MRI, CT Scan, ePRO), By End-use (Hospital, Diagnostic Centers, Ambulatory Surgical centers, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the Global AI in Respiratory Diseases Market is expected to show a CAGR of 29.4% during a forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2055

Artificial Intelligence (AI) is increasingly recognized as a transformative tool in the diagnosis, management, and research of respiratory diseases, delivering innovative solutions that enhance both clinical decision-making and patient care outcomes. Timely and precise diagnostic techniques are critical for the effective management of respiratory conditions, and AI technologies are proving instrumental in advancing these capabilities.

The market for AI applications in respiratory diseases is primarily fueled by the growing utilization of high-resolution computed tomography (CT) in diagnosing fibrotic lung disorders. For example, idiopathic pulmonary fibrosis can now be identified with high accuracy using non-invasive high-resolution CT imaging that displays hallmark features of usual interstitial pneumonia, thereby reducing the need for lung biopsies. Moreover, the rising global prevalence of chronic respiratory illnesses continues to drive the integration of AI tools into clinical practice.

The rapid expansion of healthcare data-driven by progress in areas such as genomics, medical imaging, and electronic health records-has resulted in unprecedented data volumes and complexity. This surge in information has supported the development of diverse AI-based solutions with substantial clinical and therapeutic applications. However, the growth of this market may face limitations due to a lack of public awareness about alternative treatment options for respiratory infections, which could impede the broader adoption of AI-enabled healthcare technologies in this field.

List of Prominent Players in the AI in Respiratory Diseases Market:
• ArtiQ
• Dectrocel Healthcare
• DeepMind Health
• GE Healthcare
• Icometrix
• Infervision
• Philips Healthcare
• PneumoWave
• Respiray
• Siemens Healthineers
• Swaasa AI
• THIRONA
• Verily
• VIDA Diagnostics Inc
• Zynnon

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The rising adoption of Artificial Intelligence (AI) in respiratory disease management is largely propelled by the global transition toward personalized medicine. As healthcare increasingly emphasizes individualized treatment-based on a patient's genetic makeup, lifestyle factors, and environmental influences-AI technologies are becoming essential in delivering targeted and precise care. The trend toward personalized interventions is accelerating the integration of AI, facilitating more accurate diagnostics and more effective therapeutic planning.

Challenges:
Despite the sector's promising potential, several obstacles may hinder the growth of AI in the respiratory diseases market. These include limited public awareness of non-traditional treatment modalities, stringent regulatory frameworks, and concerns about potential adverse effects of AI-guided therapies, particularly in low- and middle-income regions. In addition, pandemic-related disruptions such as lockdowns and restricted healthcare access have negatively impacted market momentum.

Nevertheless, the rising global incidence of chronic conditions-including chronic obstructive pulmonary disease (COPD), cardiovascular disorders, diabetes, and cancer-continues to highlight the importance of AI-based interventions. The COVID-19 pandemic, in particular, has underscored the strategic value of AI in navigating public health crises and improving the understanding of complex respiratory conditions, thereby reinforcing the technology's relevance in this field.

Regional Trends:
North America is projected to maintain a leadership position in the global AI in respiratory diseases market, driven by robust investments in pharmaceutical R&D, advanced technological infrastructure, and continued innovation in AI applications. The region's strong focus on digital transformation in healthcare and heightened awareness of AI's clinical advantages are expected to support ongoing market expansion.

Meanwhile, Europe is emerging as a key regional player, supported by greater availability of therapeutics, increasing public engagement, and growing interest in AI-enabled respiratory solutions. The presence of prominent industry participants and collaborative efforts among healthcare stakeholders are further positioning Europe as a hub for AI innovation in respiratory care, offering significant opportunities for international growth and development.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2055

Recent Developments:
• In August 2023, Siemens Healthineers introduced the Acuson Origin1, a cardiovascular ultrasound system equipped with advanced AI functions. By addressing diagnostic, structural heart, electrophysiological, and pediatric treatments, the Acuson Origin aims to enhance patient outcomes and aid clinicians in performing minimally invasive cardiac procedures more effectively.
• In Nov 2021, A collaborative agreement has been established between GE Healthcare and Optellum with the aim of advancing the precision diagnosis & treatment of lung cancer. The collective efforts of these firms aim to tackle a significant obstacle in the detection of lung cancer, specifically aiding healthcare personnel in accurately assessing the cancerous nature of a lung nodule.

Segmentation of AI in Respiratory Diseases Market-
By Indication-
• Chronic Obstructive Pulmonary Disease
• Interstitial Lung Disease
• Pulmonary Infection
By Imaging Type -
• MRI
• CT Scan
• ePRO
By End-use -
• Hospital
• Diagnostic Centers
• Ambulatory Surgical centers
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/ai-in-respiratory-diseases-market/2055

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.